Accuray announces first phase of comprehensive strategic, operational, and organizational transformation plan; company expects first phase to improve annualized operating profitability by approximately $25 million and set the stage for renewed growth

Stock Information for Cellectar Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cellectar Biosciences Inc.

Accuray Reports Fiscal 2026 First Quarter Financial Results
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
Accuray to Report First Quarter Fiscal 2026 Financial Results on November 5, 2025
Accuray Accelerates Transformation Efforts with Appointment of Experienced Executive Leaders to Drive Performance and Growth
Accuray Announces Milestone for Cancer Patients in Melbourne, Australia with First SBRT Treatments Using the CyberKnife® System
Accuray and the University of Wisconsin-Madison Announce Memorandum of Understanding to Advance Online Adaptive Radiotherapy in Support of Improving Cancer Patient Care
Accuray Launches All-in-One Radiotherapy Solution With Advanced Capabilities Designed to Set a New Standard in Cancer Care
Accuray to Host Analyst Event at the American Society of Radiation Oncology Meeting on September 29, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.